NASDAQ:OLMA

Olema Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy OLMA

*Your capital is at risk

$11.45

-0.370 (-3.13%)

At Close: Jul 31, 2026

Olema Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -49.61. In total, the insiders bought 3.92M and sold 1.28M OLMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-49.61
● Buy	3.92M shares
● Sell	1.28M shares
62% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -49.61. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 02, 2026 Buy	Performance Stock Options (Right to Buy) A-Award	Bohen Sean President And CEO	CEO / President	275 000 Value: $7.05M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Zojwalla Naseem Chief Medical Officer	Officer	250 000 Value: $6.41M
Feb 02, 2026 Buy	Performance Stock Options (Right to Buy) A-Award	Zojwalla Naseem Chief Medical Officer	Officer	106 250 Value: $2.73M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	250 000 Value: $6.41M
Feb 02, 2026 Buy	Performance Stock Options (Right to Buy) A-Award	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	106 250 Value: $2.73M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Mitchell Shawnte Chief Legal Officer	Officer	220 000 Value: $5.64M
Feb 02, 2026 Buy	Performance Stock Options (Right to Buy) A-Award	Mitchell Shawnte Chief Legal Officer	Officer	56 250 Value: $1.44M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Bohen Sean President And CEO	CEO / President	850 000 Value: $21.8M
Feb 01, 2026 Buy	Stock Option (Right to Buy)	Austin Sasha Lu Vp Of Finance And Controller	Officer	13 000 Value: $31.7K
Jan 30, 2026 Buy	Stock Option (Right to Buy)	Austin Sasha Lu Vp Of Finance And Controller	Officer	51 000 Value: $777.8K
Jan 30, 2026 Buy	Stock Option (Right to Buy)	Austin Sasha Lu Vp Of Finance And Controller	Officer	6 500 Value: $31.7K
Jan 30, 2026 Buy	Common Stock	Austin Sasha Lu Vp Of Finance And Controller	Officer	0 Value: $0
Jan 30, 2026 Buy	Stock Option (Right to Buy)	Austin Sasha Lu Vp Of Finance And Controller	Officer	17 500 Value: $61.1K
Jan 30, 2026 Buy	Stock Option (Right to Buy)	Austin Sasha Lu Vp Of Finance And Controller	Officer	45 000 Value: $196.7K
Jan 20, 2026 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	10 000 Value: $268.8K
Jan 15, 2026 Sell	Common Stock S-Sale	Kovacs Shane William Charles Ch. Operating & Financial Off.	Officer	100 000 Value: $2.87M
Jan 14, 2026 Sell	Common Stock S-Sale	Harmon Cyrus Director	Director	3 489 Value: $101.6K
Jan 14, 2026 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	14 997 Value: $428.9K
Jan 14, 2026 Buy	Common Stock M-Exempt	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	50 000 Value: $243.5K
Jan 14, 2026 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	35 003 Value: $1.01M
Jan 14, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	50 000 Value: $243.5K
Jan 13, 2026 Sell	Common Stock S-Sale	Kovacs Shane William Charles Ch. Operating & Financial Off.	Officer	3 822 Value: $107.1K
Jan 13, 2026 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	49 800 Value: $1.37M
Jan 13, 2026 Sell	Common Stock S-Sale	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	200 Value: $6K
Jan 13, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Myles David C. Ch. Discov. & Non-clin Dev Off	Officer	50 000 Value: $243.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...

Read Full Profile Here